<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Causes and pathophysiology of the sideroblastic anemias</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Causes and pathophysiology of the sideroblastic anemias</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Causes and pathophysiology of the sideroblastic anemias</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sylvia S Bottomley, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert T Means, Jr, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sideroblastic anemias are anemias in which ring sideroblasts are present on the bone marrow aspirate smear stained for iron with Prussian blue. Ring sideroblasts are found in diverse circumstances, which underscores a broad spectrum of causes of sideroblastic anemia, both inherited and acquired (<a class="graphic graphic_table graphicRef79712" href="/z/d/graphic/79712.html" rel="external">table 1</a>). Understanding the causative mechanisms is useful for predicting the disease course and guiding therapy, which differ for the various sideroblastic anemia forms.</p><p>This topic review discusses the recognized congenital and acquired causes of the sideroblastic anemias and their pathophysiology. The clinical presentations and diagnostic testing for specific forms of sideroblastic anemia, and our approach to patient management, are presented in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7123.html" rel="external">"Sideroblastic anemias: Diagnosis and management"</a>.)</p><p class="headingAnchor" id="H1748145852"><span class="h1">CAUSES OF SIDEROBLASTIC ANEMIAS</span><span class="headingEndMark"> — </span>The conventional classification of the sideroblastic anemias is structured on whether the cause is congenital (inherited) or acquired, followed by listing genetic defects or environmental factors (<a class="graphic graphic_table graphicRef79712" href="/z/d/graphic/79712.html" rel="external">table 1</a>) [<a href="#rid1">1,2</a>]. In searching for the cause it can also be helpful to note whether the anemia is microcytic or normocytic/macrocytic (<a class="graphic graphic_table graphicRef108664" href="/z/d/graphic/108664.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H3595966943"><span class="h2">Congenital sideroblastic anemias</span><span class="headingEndMark"> — </span>Congenital sideroblastic anemias are caused by a germline pathogenic variant affecting a nuclear or mitochondrial gene. For a number of forms, underlying defects have been established at the molecular level, as illustrated in the diagram (<a class="graphic graphic_figure graphicRef86551" href="/z/d/graphic/86551.html" rel="external">figure 1</a>). However, approximately one-third of cases do not have an identifiable genetic defect as of yet [<a href="#rid3">3-5</a>]. The causative defects for these patients are actively being sought in research laboratories. </p><p>The congenital sideroblastic anemias can be subdivided into nonsyndromic and syndromic forms (<a class="graphic graphic_table graphicRef79712" href="/z/d/graphic/79712.html" rel="external">table 1</a>), by their mode of inheritance (X-linked, autosomal recessive, or mitochondrial) or according to red blood cell size (microcytic or normocytic-to-macrocytic) (<a class="graphic graphic_table graphicRef108664" href="/z/d/graphic/108664.html" rel="external">table 2</a>). The majority appear as nonsyndromic, with isolated anemia and ring sideroblasts in the bone marrow. The syndromic forms, which affect other organ systems, are very uncommon.</p><p class="headingAnchor" id="H216940404"><span class="h3">Nonsyndromic forms</span><span class="headingEndMark"> — </span>Most congenital sideroblastic anemias are nonsyndromic. They can be X-linked, referred to as X-linked sideroblastic anemia (XLSA) or autosomal recessive, referred to as autosomal recessive congenital sideroblastic anemia (ARCSA).</p><p class="headingAnchor" id="H2844197457"><span class="h4">X-linked sideroblastic anemia (<i>ALAS2</i> mutation)</span><span class="headingEndMark"> — </span>X-linked sideroblastic anemia (XLSA) was first described in the 1940s. In the 1990s, linkage to the <em>ALAS2</em> locus (the erythroid-specific form of 5-aminolevulinate synthase) was established in several kindreds [<a href="#rid1">1</a>]. The ALAS2 enzyme catalyzes the first and rate-limiting step in heme synthesis (condensation of glycine and succinyl-CoA to ALA) (<a class="graphic graphic_figure graphicRef66466" href="/z/d/graphic/66466.html" rel="external">figure 2</a>) and is essential for erythroid cell development [<a href="#rid6">6,7</a>]. (See <a class="local">'Heme synthesis'</a> below.)</p><p>Over 100 distinct pathogenic variants in <em>ALAS2</em> have been identified among more than 130 unrelated kindreds or probands. These variants are most often missense mutations that affect the catalytic domain of ALAS2 and reduce enzymatic function in many but not all cases [<a href="#rid1">1,8</a>]. Uncommon are nonsense mutations, nucleotide deletions, synonymous coding variant altering <em>ALAS2</em> splicing, mutations in a GATA1 transcription factor binding site in intron 1, and regulatory mutations in the <em>ALAS2</em> promoter region; null mutations are seen only in heterozygous females [<a href="#rid1">1,8-11</a>].</p><p><em>ALAS2</em> is located on the X chromosome [<a href="#rid12">12,13</a>]. Although XLSA is most commonly seen in males, nearly one-third of affected individuals are females who manifest the disorder because they develop highly skewed X inactivation in hematopoietic cells, favoring expression of the mutant allele [<a href="#rid14">14-17</a>]. (See  <a class="medical medical_review" href="/z/d/html/7123.html" rel="external">"Sideroblastic anemias: Diagnosis and management", section on 'Diagnostic approach'</a>.)</p><p class="headingAnchor" id="H2882891952"><span class="h4">Autosomal recessive congenital sideroblastic anemia (pathogenic variant in <i>SLC25A38</i>, <i>GLRX5</i>, <i>HSPA9</i>, <i>HSCB</i>, or <i>FECH</i>)</span><span class="headingEndMark"> — </span>Pathogenic variants in several genes involved in heme synthesis cause autosomal recessive congenital sideroblastic anemia (ARCSA) (<a class="graphic graphic_figure graphicRef86551" href="/z/d/graphic/86551.html" rel="external">figure 1</a>). Among the ARCSAs, the one associated with <em>SLC25A38</em> mutations is the most common, second only to XLSA in occurrence [<a href="#rid18">18</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>SLC25A38</em></strong> – <em>SLC25A38</em> encodes an erythroid-specific mitochondrial amino acid carrier that transports glycine into mitochondria for the first step in heme synthesis [<a href="#rid19">19</a>]. Multiple biallelic mutations in the <em>SLC25A38</em> gene associated with congenital sideroblastic anemia have been identified in at least 93 families or probands [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>HSPA9</em></strong><strong> and </strong><strong><em>HSCB</em></strong> – <em>HSPA9</em> encodes the mitochondrial HSP70 homologue HSPA9, which is also involved in Fe-S cluster biogenesis. Heterogeneous biallelic mutations have been discovered in 12 families or isolated cases [<a href="#rid20">20,21</a>]. In one patient, biallelic mutations in <em>HSCB</em>, which encodes a co-chaperone of HSPA9, are reported [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>GLRX5</em></strong> – <em>GLRX5</em> encodes a small protein required for the synthesis of iron-sulfur (Fe-S) clusters, prosthetic groups that are essential components of various mitochondrial and cytosolic proteins, including iron regulatory protein 1 (IRP1) and ferrochelatase (FECH) [<a href="#rid23">23</a>]. In a zebrafish mutant (shiraz) deficient in GLRX5, IRP1 cannot acquire the Fe-S cluster and thus inhibits <em>ALAS2</em> translation, causing severe hypochromic anemia [<a href="#rid24">24</a>]. Homozygous and heterozygous biallelic pathogenic variants in <em>GLRX5</em> have been described in three patients [<a href="#rid25">25-27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>FECH</em></strong> – <em>FECH</em> encodes ferrochelatase, the final enzyme in the heme synthetic pathway, which inserts an iron atom into protoporphyrin IX (<a class="graphic graphic_figure graphicRef66466" href="/z/d/graphic/66466.html" rel="external">figure 2</a>). Mutations in <em>FECH</em> cause erythropoietic protoporphyria (EPP), in which patients develop acute, nonblistering cutaneous photosensitivity due to accumulation of excess free protoporphyrin. Most if not all individuals with EPP have mild microcytic anemia. Ring sideroblasts have been documented in only 10 patients but not in others [<a href="#rid28">28-30</a>]. A systematic study of the frequency of ring sideroblasts in EPP has not been performed. EPP is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7125.html" rel="external">"Erythropoietic protoporphyria and X-linked protoporphyria"</a>.)</p><p></p><p class="headingAnchor" id="H3891750111"><span class="h3">Syndromic forms</span><span class="headingEndMark"> — </span>Syndromic congenital sideroblastic anemias have other, nonhematologic manifestations such as neuromuscular and metabolic abnormalities in addition to the ring sideroblast feature (<a class="graphic graphic_table graphicRef79712" href="/z/d/graphic/79712.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef108664" href="/z/d/graphic/108664.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H1876422901"><span class="h4">X-linked sideroblastic anemia with ataxia (<i>ABCB7</i> mutation)</span><span class="headingEndMark"> — </span>X-linked sideroblastic anemia with ataxia (XLSA/A) is a rare phenotype of congenital sideroblastic anemia, characterized by relatively mild anemia and nonprogressive spinocerebellar ataxia [<a href="#rid31">31</a>]. The molecular defect resides in the <em>ABCB7 </em>gene, which is located on the X chromosome. It encodes an essential transporter in the inner mitochondrial membrane [<a href="#rid32">32</a>]. This transporter is involved in the transfer of Fe-S clusters into the cytoplasm for assembly of cytoplasmic Fe-S cluster-containing proteins [<a href="#rid33">33</a>]. Several mutations have been described and cause partial loss of function of the transporter protein [<a href="#rid33">33-36</a>]. (See <a class="local">'Iron-sulfur (Fe-S) cluster biogenesis'</a> below.)</p><p class="headingAnchor" id="H3648145734"><span class="h4">Myopathy, lactic acidosis, and sideroblastic anemia (pathogenic variants in <i>IARS2</i>, <i>LARS2</i>, <i>MT-ATP6</i>, <i>NDUFB11</i>, <i>PUS1</i>, <i>SARS2</i>, or <i>YARS2</i>)</span><span class="headingEndMark"> — </span>Myopathy, lactic acidosis, and sideroblastic anemia (MLASA) was first defined as an autosomal recessive oxidative phosphorylation disorder in 2004, characterized by progressive exercise intolerance during childhood, onset of sideroblastic anemia usually around adolescence, basal lactic acidemia, and mitochondrial myopathy due to mutation of <em>PUS1</em> (pseudouridine synthase 1) [<a href="#rid37">37,38</a>]. The <em>IARS2</em>, <em>LARS2</em>, <em>PUS1</em>, <em>SARS2</em>, and <em>YARS2</em> variants are also autosomal recessive, while those associated with a recurrent mutation of <em>NDUFB11 </em>or <em>MT-ATP6</em> are X-linked and maternally inherited, respectively. (See  <a class="medical medical_review" href="/z/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis", section on 'Predominantly multisystem disease with myopathy'</a>.)</p><p>Pathogenic variants in the <em>IARS2, LARS2</em>, <em>MT-ATP6</em>, <em>NDUFB11</em>, <em>PUS1,</em> <em>SARS2, </em>and <em>YARS2 </em>genes are found in individuals with, in part, similar syndromic findings, ranging from mild (not detected until adulthood) to lethal in severity [<a href="#rid38">38-47</a>]; among cases with <em>YARS2</em> defects, isolated sideroblastic anemia without syndromic features has been noted [<a href="#rid44">44</a>]. Five nuclear genes (<em>IARS2, LARS2, PUS1, SARS2 </em>and<em> YARS2</em>) involve mitochondrial protein translation, while <em>NDUFB11</em> encodes a component of the respiratory chain complex I [<a href="#rid41">41,48</a>]. Mitochondrial <em>MT-ATP6</em> encodes ATPase 6, a component of complex V (ATPase) [<a href="#rid40">40,45</a>]. (See <a class="local">'Mitochondrial protein synthesis'</a> below.)</p><p class="headingAnchor" id="H3532598785"><span class="h4">Sideroblastic anemia, B cell immunodeficiency, periodic fevers, and developmental delay (<i>TRNT1</i> mutation)</span><span class="headingEndMark"> — </span>Sideroblastic anemia, B cell immunodeficiency, periodic fevers, and developmental delay (SIFD; also called ARCSA with immunodeficiency) is a congenital syndromic immunodeficiency associated with severe microcytic sideroblastic anemia, B cell lymphopenia, panhypogammaglobulinemia, periodic fevers and developmental delay, with onset in infancy [<a href="#rid49">49,50</a>]. Neurodegeneration, seizures, cerebellar abnormalities, sensorineural deafness, and other multisystem derangements are variably present. Subsequent case studies have expanded the spectrum of clinical features even further, including milder phenotypes such as manifesting only isolated anemia or immunodeficiency, or isolated nonsyndromic retinitis pigmentosa with microcytic red blood cells [<a href="#rid51">51,52</a>]. Early death was commonly attributed to cardiac or multiorgan failure. This syndrome and the management of its inflammatory component are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/122509.html" rel="external">"Autoinflammatory diseases mediated by miscellaneous mechanisms", section on 'SIFD syndrome'</a>.)</p><p>SIFD is caused by biallelic pathogenic variants affecting <em>TRNT1 </em>[<a href="#rid50">50</a>]; this nuclear gene encodes the essential enzyme tRNA nucleotidyl transferase (also called CCA-adding enzyme) that adds CCA to the end of all nuclear and mitochondrial transfer RNAs before they can engage in the polypeptide assembly on ribosomes. Transmission is autosomal recessive, and parental consanguinity was present in several instances [<a href="#rid49">49-52</a>]. (See <a class="local">'Mitochondrial protein synthesis'</a> below.)</p><p class="headingAnchor" id="H4164251981"><span class="h4">Pearson syndrome (large deletion of mitochondrial DNA)</span><span class="headingEndMark"> — </span>Pearson syndrome (Pearson marrow pancreas syndrome) is a congenital multisystem disorder characterized by severe sideroblastic anemia, milder neutropenia and thrombocytopenia, pancreatic insufficiency, lactic acidosis, and failure to thrive from infancy or early childhood. New observations have broadened the phenotypic spectrum of the syndrome to patients with onset later than previously reported [<a href="#rid53">53</a>]. There may be atypical disease presentations that cause the diagnosis to be overlooked or misattributed to other conditions. (See  <a class="medical medical_review" href="/z/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis", section on 'Pearson syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/5914.html" rel="external">"Shwachman-Diamond syndrome", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/5877.html" rel="external">"Overview of the causes of chronic diarrhea in children in resource-abundant settings", section on 'Pancreatic exocrine insufficiency'</a>.)</p><p>The syndrome is caused by large deletions or rearrangements of mitochondrial DNA, resulting in the loss of multiple proteins and transfer RNAs encoded by the mitochondrial genome [<a href="#rid54">54</a>]. These major molecular defects are associated with pronounced abnormalities in the ultrastructure of erythroblast mitochondria [<a href="#rid55">55</a>]. (See <a class="local">'Disrupted mitochondrial pathways in erythroid precursors'</a> below.)</p><p class="headingAnchor" id="H2072766856"><span class="h4">Thiamine-responsive megaloblastic anemia (<i>SLC19A2</i> mutation)</span><span class="headingEndMark"> — </span>Thiamine-responsive megaloblastic anemia (TRMA, also called Rogers syndrome) is a congenital syndrome characterized by megaloblastic anemia, diabetes mellitus, and sensorineural deafness manifesting between infancy and adolescence [<a href="#rid56">56</a>]. Hematologic findings also include the ring sideroblast abnormality and variable degrees of neutropenia and thrombocytopenia. (See  <a class="medical medical_review" href="/z/d/html/7166.html" rel="external">"Macrocytosis/Macrocytic anemia", section on 'Megaloblastic anemia'</a>.)</p><p>TRMA is caused by mutations in the <em>SLC19A2</em> gene, which encodes a high-affinity thiamine transporter protein, with various mutations identified in many families [<a href="#rid56">56-59</a>]. Transmission is autosomal recessive.</p><p class="headingAnchor" id="H514817387"><span class="h2">Acquired sideroblastic anemias</span><span class="headingEndMark"> — </span>Acquired sideroblastic anemias are subdivided into the clonal forms (myelodysplastic syndromes with ring sideroblasts [MDS-RS]) and the forms that are reversible, due to an exposure or deficiency that affects aspects of erythroblast iron handling (<a class="graphic graphic_table graphicRef79712" href="/z/d/graphic/79712.html" rel="external">table 1</a>). In the reversible forms such as exposure to ethanol and certain drugs, copper deficiency, and hypothermia, the sideroblastic anemia resolves when the cause is corrected. Most of the acquired sideroblastic anemias are normocytic or macrocytic (<a class="graphic graphic_table graphicRef108664" href="/z/d/graphic/108664.html" rel="external">table 2</a>). Exceptions are exposure to <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> and alcohol, which cause microcytic anemia. Excessive alcohol may also cause macrocytosis. (See  <a class="medical medical_review" href="/z/d/html/7151.html" rel="external">"Hematologic complications of alcohol use", section on 'Anemia'</a>.)</p><p class="headingAnchor" id="H2783675900"><span class="h3">Clonal (MDS/MPN subtypes)</span><span class="headingEndMark"> — </span>Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) are clonal hematopoietic disorders, typically acquired in adulthood. They are characterized by dysplastic maturation and ineffective production of erythrocytes, granulocytes, and/or platelets. Ring sideroblasts are present in the following MDS or MDS/MPN variants [<a href="#rid60">60</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MDS-RS-SLD</strong> – MDS with ring sideroblasts and single lineage dysplasia (MDS-RS-SLD)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MDS-RS-MLD</strong> – MDS with ring sideroblasts and multilineage dysplasia (MDS-RS-MLD)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MDS/MPN-RS-T</strong> – MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)</p><p></p><p>A very close association between the ring sideroblast feature in these MDS/MPN variants and specific somatic mutations in genes implicated in mRNA splicing suggested a causal relationship.</p><p>The <em>SF3B1</em> gene, which encodes the spliceosome component SF3B1 (splicing factor 3B, subunit 1), is mutated in 70 to 90 percent of cases of MDS with ring sideroblasts and only infrequently in MDS without ring sideroblasts (&lt;10 percent) [<a href="#rid61">61-64</a>]. A pharmacologic inhibitor of SF3B splicing function was found to induce ring sideroblasts in human cells, also supporting a causative role of the mutations in the ring sideroblast abnormality [<a href="#rid65">65</a>]. (See <a class="local">'Pathophysiology'</a> below.)</p><p>Some cases of the MDS/MPN subtypes have been associated with other acquired genetic defects including loss of a <em>FECH </em>allele, <em>JAK2</em> mutation, mitochondrial DNA mutation, and other alterations affecting the RNA splicing machinery [<a href="#rid62">62,63,66,67</a>]. The genetic changes in MDS are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4483.html" rel="external">"Cytogenetics, molecular genetics, and pathophysiology of myelodysplastic syndromes/neoplasms (MDS)"</a>.)</p><p class="headingAnchor" id="H2396614502"><span class="h3">Reversible</span><span class="headingEndMark"> — </span>The defining feature of acquired sideroblastic anemias other than the MDS/MPN forms is the reversibility following correction of the underlying abnormality (assuming it can be identified).</p><p class="headingAnchor" id="H1842429360"><span class="h4">Alcohol</span><span class="headingEndMark"> — </span>The ring sideroblast abnormality is one of many components contributing to the anemia associated with excess alcohol use. In a study involving 121 individuals with chronic alcohol use and anemia, ring sideroblasts were documented in 23 percent but were always accompanied by at least one other abnormality such as <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> deficiency or malnutrition [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/7151.html" rel="external">"Hematologic complications of alcohol use"</a>.)</p><p class="headingAnchor" id="H1135990277"><span class="h4">Medications</span><span class="headingEndMark"> — </span>Certain medications have been found to produce sideroblastic anemia. Classic examples include the anti-tuberculosis drug <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> and the antibacterial antibiotics <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">chloramphenicol</a> and <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">Isoniazid</a><strong> (INH)</strong> – While INH has been extensively used to treat tuberculosis for over six decades, sideroblastic anemia associated with its use has been documented in only a few dozen case studies. The apparent low incidence has been attributed at least in part to the regular co-administration of <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a> (vitamin B6) to prevent the common INH-induced neuropathy (see  <a class="medical medical_review" href="/z/d/html/481.html" rel="external">"Isoniazid: An overview", section on 'Dosing and administration'</a>). It has also been suggested that an occult hematologic abnormality in some individuals may make them more susceptible. High-quality evidence that the related drugs <a class="drug drug_general" data-topicid="9836" href="/z/d/drug information/9836.html" rel="external">pyrazinamide</a> and <a class="drug drug_general" data-topicid="9309" href="/z/d/drug information/9309.html" rel="external">cycloserine</a> cause sideroblastic anemia is lacking.</p><p></p><p class="bulletIndent1">INH interference with <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a> metabolism and thus with the function of the ALAS2 enzyme is considered to be the basis for sideroblastic anemia occurring in some individuals. The anemia is reversed by discontinuing the INH or by pyridoxine supplementation. (See <a class="local">'Heme synthesis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">Chloramphenicol</a><strong> and </strong><a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> – Chloramphenicol was well documented to cause a sideroblastic anemia in a dose-dependent manner in the remote past [<a href="#rid69">69</a>]. The association of sideroblastic anemia with linezolid use was described more recently [<a href="#rid70">70-72</a>]. Both of these drugs inhibit mitochondrial protein synthesis. (See <a class="local">'Mitochondrial protein synthesis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytotoxic chemotherapy</strong> – Anecdotal cases over 40 years ago suggested that when sideroblastic anemia followed chemotherapy for hematologic malignancies, subsequent leukemic evolution was the rule [<a href="#rid1">1</a>]. The role of the ring sideroblast abnormality in therapy-related myelodysplastic syndrome (t-MDS) was subsequently explored. In a study involving 843 patients who were initially diagnosed as having secondary MDS months to years following cytotoxic chemotherapy for various malignancies, 19 had a normal karyotype, &lt;5 percent blasts in the bone marrow, and abundant ring sideroblasts [<a href="#rid73">73</a>]. Six of these 19 (32 percent) had normalization of the complete blood count (CBC) and resolution of signs of dyserythropoiesis and the ring sideroblast abnormality on subsequent bone marrow examinations, indicating that they had a reversible sideroblastic anemia rather than MDS, although a specific cause could not be identified. In a later study comparing 38 patients having t-MDS and ring sideroblasts (t-MDS-RS) with 174 patients having de novo MDS and ring sideroblasts (de novo MDS-RS), the t-MDS-RS cohort had the following features [<a href="#rid74">74</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A higher prognostic risk by cytogenetic score and revised international prognostic scoring system for MDS (IPSS-R), often carrying pathogenic variants in <em>TP53.</em></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Less commonly, pathogenic variants in <em>SF3B1</em> and spliceosome-related genes (approximately 33 percent versus approximately 75 percent), suggesting other mechanisms for the ring sideroblast feature.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A worse outcome, similar to that of t-MDS without ring sideroblasts. </p><p></p><p class="bulletIndent1">Attention to the "short-term gain but long-term pain" from cytotoxic chemotherapy as reflected in the risk of t-MDS in general is gaining momentum [<a href="#rid75">75</a>]. Prevention strategies have been proposed such as revision of chemotherapy agent use (eg, alkylating agents) and clinical sequencing at diagnosis to aid identification of patients at risk for t-MDS.<strong> </strong></p><p></p><p class="headingAnchor" id="H3971608847"><span class="h4">Hypothermia</span><span class="headingEndMark"> — </span>A sideroblastic abnormality has been described in three patients with episodic hypothermia [<a href="#rid76">76</a>]. This cause was thought to involve the known sensitivity of several mitochondrial functions to reduced temperature (eg, translocation of proteins into mitochondria, heme synthesis, and iron incorporation into hemoglobin) [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3621705286"><span class="h4">Copper deficiency</span><span class="headingEndMark"> — </span>Although uncommon, copper deficiency is a cause of sideroblastic anemia, along with neutropenia, and is commonly accompanied by various neurologic deficits. There are several settings in which copper deficiency can develop, including small bowel disorders, bariatric surgery, prolonged enteral or <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> without copper supplementation, use of the chelating agent <a class="drug drug_general" data-topicid="10019" href="/z/d/drug information/10019.html" rel="external">trientine</a> (triethylene tetramine dihydrochloride; TTH), and excess zinc ingestion. (See  <a class="medical medical_review" href="/z/d/html/7123.html" rel="external">"Sideroblastic anemias: Diagnosis and management", section on 'Copper deficiency'</a>.)</p><p>A rare cause of copper deficiency was reported in an infant with a familial nephrotic syndrome associated with a mutation in the <em>NPHS2</em> gene, which encodes a renal glomerular protein implicated in nephrotic syndrome. The presumed mechanism was attributed to urinary losses of ceruloplasmin and copper. </p><p class="headingAnchor" id="H1085033313"><span class="h3">Transient sideroblastic anemia during pregnancy</span><span class="headingEndMark"> — </span>Several reports have described sideroblastic anemia manifesting during pregnancy [<a href="#rid77">77,78</a>]. The sideroblastic anemia recurred in successive pregnancies or was detected postpartum. Molecular analysis for a hereditary cause was not performed in these cases. </p><p>In one instance, low vitamin B6 level was documented and supplements increased the Hb level [<a href="#rid77">77</a>]. A carrier state of a genetic variant that becomes clinically expressed is a possibility in these individuals and should be excluded. For example, an otherwise clinically occult pathogenic variant in <em>ALAS2</em> (XLSA) may become expressed if there is skewed X inactivation, and the anemia would respond to <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a> supplementation as vitamin B6 stores can be reduced during pregnancy. Explanation of this unusual occurrence requires at least molecular studies as well as comprehensive data that are lacking on nutritional sufficiency of vitamin B6 during pregnancy generally. (See  <a class="medical medical_review" href="/z/d/html/453.html" rel="external">"Nutrition in pregnancy: Dietary requirements and supplements", section on 'Vitamin B6'</a>.)</p><p class="headingAnchor" id="H1174919368"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The causes of sideroblastic anemia most often lead to defective maturation of developing erythroid cells (erythroblasts) from disturbances in the production of heme for hemoglobin. In this setting, the bone marrow characteristically responds to the anemic hypoxia by increasing erythropoiesis, which is ineffective due to the maturation defects. Moreover, the ineffective erythropoiesis itself elicits an associated systemic iron overload state that influences clinical features and prognosis. (See <a class="local">'Iron overload'</a> below and  <a class="medical medical_review" href="/z/d/html/7123.html" rel="external">"Sideroblastic anemias: Diagnosis and management", section on 'Laboratory and bone marrow findings'</a>.)</p><p class="headingAnchor" id="H2898858285"><span class="h2">Disrupted mitochondrial pathways in erythroid precursors</span><span class="headingEndMark"> — </span>Mitochondria of developing erythroid cells play a central role in the pathogenesis of all sideroblastic anemias (<a class="graphic graphic_figure graphicRef86551" href="/z/d/graphic/86551.html" rel="external">figure 1</a>) as they are the cellular site of heme production and iron utilization. Primary defects in components of iron trafficking pathways are not known to be involved. Rather, each known cause that leads to a sideroblastic anemia disrupts one or more of four mitochondrial metabolic pathways [<a href="#rid2">2,79</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Heme synthesis</p><p class="bulletIndent1"><span class="glyph">●</span>Iron sulfur-cluster production</p><p class="bulletIndent1"><span class="glyph">●</span>Mitochondrial protein synthesis</p><p class="bulletIndent1"><span class="glyph">●</span>Oxidative phosphorylation</p><p></p><p>In sideroblastic anemias, iron is delivered to erythroblast mitochondria normally [<a href="#rid80">80,81</a>]. However, the disrupted mitochondrial pathway(s) blocks the iron utilization that occurs exclusively in mitochondria, and a feedback mechanism to reduce iron import into mitochondria is not known. Consequently, iron accumulates in the mitochondrial matrix as mitochondrial ferritin, forming the ring sideroblast [<a href="#rid82">82,83</a>]. This diagnostic feature of any sideroblastic anemia is detected on the iron-stained bone marrow aspirate smear, revealing erythroblasts containing numerous coarse blue "granules" that characteristically appear strung out like a necklace or a ring around the cell nuclei (<a class="graphic graphic_picture graphicRef62536" href="/z/d/graphic/62536.html" rel="external">picture 1</a>). Ultrastructurally, the granules represent pathological, iron-laden mitochondria (<a class="graphic graphic_picture graphicRef62536" href="/z/d/graphic/62536.html" rel="external">picture 1</a>).</p><p class="headingAnchor" id="H409898431"><span class="h3">Heme synthesis</span><span class="headingEndMark"> — </span>Although heme synthesis occurs in all nucleated cells, developing red blood cells (RBCs) have the greatest heme requirement of any cell type. Hemoglobin contains nearly 80 percent of the body heme and therein more than two-thirds of the body iron. The heme biosynthesis pathway involves a sequential assembly of the porphyrin ring from glycine and succinyl-coenzyme A (CoA) and also the concerted shuttling of intermediates from mitochondria to cytosol and back again, with heme ultimately being formed by insertion of ferrous iron into protoporphyrin IX (<a class="graphic graphic_figure graphicRef66466" href="/z/d/graphic/66466.html" rel="external">figure 2</a>).</p><p>Exceptionally robust erythroid heme production is made possible by the expression of an erythroid-specific form of 5-aminolevulinate (ALA) synthase (ALAS2), as well as the presence of erythroid-specific promoters in the genes encoding subsequent enzymes in the heme synthesis pathway [<a href="#rid1">1</a>]. The transcriptional expression of these enzymes is mediated by erythroid-specific factors, similar to many other genes that are differentially regulated in erythroid cells. In addition, translational regulation is important for ALAS2 expression; this occurs via interaction of the iron regulatory protein 1 (IRP1) with the ALAS2 mRNA, linking ALAS2 translation with iron availability in the cell [<a href="#rid84">84</a>].</p><p class="headingAnchor" id="H257955462"><span class="h4">Inherited disorders</span><span class="headingEndMark"> — </span>Pathogenic variants affecting proteins that are integral to erythroid heme synthesis lead to reduced heme production and microcytic RBCs (similar to iron-deficiency anemia) in three forms of microcytic congenital sideroblastic anemia:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>X-linked sideroblastic anemia</strong> – X-linked sideroblastic anemia (XLSA) is due to pathogenic variants in <em>ALAS2</em> gene, which is located on the X chromosome and encodes the first and rate-limiting enzyme of the heme synthesis pathway. The severity of anemia is highly variable and can be related to the location of the altered amino acid(s) within the ALAS2 enzyme, thereby determining its impact on the enzyme's function [<a href="#rid8">8,85,86</a>]. Despite the X-linked inheritance pattern, and in contrast with most if not all X-linked disorders, about one-third of affected individuals are female [<a href="#rid1">1</a>]. This high rate of expression in females is due to highly skewed X chromosome inactivation, which occurs in hematopoietic tissue with advancing age, favoring expression of mostly the abnormal allele. (See  <a class="medical medical_review" href="/z/d/html/2898.html" rel="external">"Genetics: Glossary of terms", section on 'X-inactivation'</a>.) </p><p></p><p class="bulletIndent1">Their pathogenic variants in<em> ALAS2</em> tend to be more damaging to the enzyme, which is reenforced by the virtual absence of male offspring of affected females [<a href="#rid1">1,15</a>]. In exceptional cases, there may be "constitutional" skewing of X chromosome inactivation that causes the disease to manifest in females earlier in life [<a href="#rid14">14</a>]. The mechanism of XLSA in a first reported female fetus is unclear [<a href="#rid87">87</a>]. (See <a class="local">'X-linked sideroblastic anemia (ALAS2 mutation)'</a> above.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">Pyridoxine</a> (vitamin B6) is converted in the liver to the active co-enzyme pyridoxal-5’-phosphate, an obligate cofactor for ALAS. In up to two-thirds of patients with XLSA, the anemia responds to pyridoxine supplements (to a variable extent) by enhancing the function of some ALAS2 mutant proteins, in particular when the mutations affect pyridoxal-5’-phosphate binding to the ALAS enzyme [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1">Two cases illustrate this phenomenon:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A patient with a de novo missense mutation in exon 5 of <em>ALAS2</em>, located within the catalytic domain of the enzyme, had reduced activity of the enzyme expressed in vitro (15 percent of normal) that was increased to 34 percent by the addition of pyridoxal-5’-phosphate; this correlated with clinical improvement upon <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">vitamin B6</a> administration [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A familial missense mutation in exon 8 of <em>ALAS2</em>, located near the pyridoxal-5’-phosphate binding site was associated with bone marrow ALAS2 activity of approximately 30 percent when the index patient was not taking <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">vitamin B6</a>; ALAS2 enzymatic activity as well as the hemoglobin level was restored to normal upon vitamin B6 administration [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mitochondrial transporter SLC25A28 variants</strong> – The erythroid-specific carrier protein SLC25A38 imports glycine across the inner mitochondrial membrane; large amounts of glycine are required as a substrate for ALAS to generate ALA [<a href="#rid19">19,90</a>]. Biallelic mutations in <em>SLC25A38</em> are associated with severe anemia from infancy [<a href="#rid18">18</a>]. Most of the mutations are complete loss-of-function mutations or severe mutations that markedly compromise the function of the protein and in turn severely impair heme synthesis. Interestingly, in one case, the condition occurred due to uniparental (paternal) isodisomy [<a href="#rid91">91</a>]. (See <a class="local">'Autosomal recessive congenital sideroblastic anemia (pathogenic variant in SLC25A38, GLRX5, HSPA9, HSCB, or FECH)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ferrochelatase deficiency</strong> – Ferrochelatase (FECH) catalyzes the final step in heme syntheses. Marked deficiency of FECH is due to numerous identified mutations affecting the enzyme, which cause the autosomal recessively (or "pseudo-dominantly") inherited erythropoietic protoporphyria (EPP). EPP is manifested in erythroid cells by marked accumulation of free protoporphyrin during the final stages of erythroblast maturation, when defective FECH becomes rate-limiting for heme production. Most patients have mild microcytic anemia. Although the presence of ring sideroblasts was only documented in 10 cases (and not found in others), iron accumulation in erythroblast mitochondria would be expected in the setting of FECH deficiency [<a href="#rid28">28-30</a>]. Ring sideroblasts may occur variably as iron uptake appears to be restricted to match the FECH deficiency [<a href="#rid92">92</a>]. (See <a class="local">'Autosomal recessive congenital sideroblastic anemia (pathogenic variant in SLC25A38, GLRX5, HSPA9, HSCB, or FECH)'</a> above.)</p><p></p><p class="headingAnchor" id="H3555336710"><span class="h4">Acquired states</span><span class="headingEndMark"> — </span>Reduced erythroid heme synthesis can be acquired, causing reversible sideroblastic anemia. (See <a class="local">'Reversible'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">Isoniazid</a><strong> (INH) administration</strong> – INH is an antituberculosis agent that interferes with the function of ALAS2 and in turn impairs heme synthesis via two apparent mechanisms (see <a class="local">'Medications'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>As a vitamin B6 antagonist, INH forms hydrazones with pyridoxal-5’-phosphate that inhibit pyridoxal phosphokinase, thus impairing the conversion of <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a> to its active cofactor form pyridoxal-5’-phosphate and depleting pyridoxal-5’-phosphate levels [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>INH inhibits the ALAS2 enzyme directly, although this has not been ascertained in human erythroblasts [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Excess alcohol use</strong> – The ring sideroblast feature and microcytic, hypochromic anemia observed with chronic alcohol use has been attributed to impairment of heme synthesis through the effect of alcohol on <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">vitamin B6</a> metabolism as well as on subsequent steps of heme synthesis [<a href="#rid69">69,94</a>]. Toxic effects on mitochondrial protein synthesis are involved, caused by ethanol, acetaldehyde, or both. (See <a class="local">'Alcohol'</a> above.)</p><p></p><p class="headingAnchor" id="H3925656997"><span class="h3">Iron-sulfur (Fe-S) cluster biogenesis</span><span class="headingEndMark"> — </span>Iron imported into mitochondria of erythroid cells is also required to generate Fe-S clusters. Fe-S clusters are essential prosthetic groups in proteins regulating cellular iron uptake, heme synthesis, and iron storage, including iron regulatory protein 1 (IRP1) as well as FECH itself [<a href="#rid95">95</a>]. Fe-S clusters are synthesized exclusively in mitochondria via a multistep process and are then incorporated into mitochondrial as well as cytoplasmic recipient proteins [<a href="#rid95">95</a>].</p><p>Three forms of sideroblastic anemia provide examples of impaired Fe-S cluster generation that secondarily impacts heme synthesis and results in microcytic RBCs.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>HSPA9 and HSCB</strong> – HSPA9 and its co-chaperone HSCB are involved in mitochondrial Fe-S cluster biogenesis and transfer of nascent Fe-S clusters to glutaredoxin 5 for their transport to target proteins [<a href="#rid2">2</a>]. Impaired HSPA9 and HSCB proteins due to heterogeneous biallelic pathogenic variants would lead secondarily to repressed ALAS2 translation, similar to that seen with <em>GLRX5</em> and <em>ABCB7</em>, discussed immediately below. In some cases, a single severe <em>HSPA9 </em>loss-of-function allele is associated with a common single nucleotide polymorphism in the other <em>HSPA9</em> allele that is under-expressed, resulting in a pseudodominant inheritance pattern [<a href="#rid20">20</a>]. (See <a class="local">'Autosomal recessive congenital sideroblastic anemia (pathogenic variant in SLC25A38, GLRX5, HSPA9, HSCB, or FECH)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glutaredoxin 5 (GLRX5) deficiency</strong> – GLRX5 distributes Fe-S clusters to Fe-S requiring proteins. Pathogenic variants in <em>GLRX5</em> result in lack of Fe-S clusters in IRP1, thereby activating IRP1 to its RNA binding form and leading to repression of ALAS2 translation and impaired heme synthesis [<a href="#rid23">23</a>]. Because FECH requires an Fe-S cluster for its function, FECH levels are also decreased. (See <a class="local">'Autosomal recessive congenital sideroblastic anemia (pathogenic variant in SLC25A38, GLRX5, HSPA9, HSCB, or FECH)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>X-linked sideroblastic anemia with ataxia (XLSA/A)</strong> – ABCB7 is a mitochondrial transporter that transfers Fe-S clusters or a mitochondrial component required for the cytosolic Fe-S cluster assembly machinery [<a href="#rid33">33,95</a>]. Pathogenic variants in <em>ABCB7</em> are associated with XLSA/A. In cell culture models, knockdown of <em>ABCB7</em> leads to loss of mitochondrial and cytosolic Fe-S proteins, defective heme biosynthesis via repression of ALAS2 and decreased stability of FECH as well as mitochondrial iron overload, triggering apoptosis of erythroid precursors, similar to GLRX5 deficiency [<a href="#rid96">96</a>]. (See <a class="local">'X-linked sideroblastic anemia with ataxia (ABCB7 mutation)'</a> above.)</p><p></p><p class="bulletIndent1">The pathogenesis of the associated neurologic manifestations is unclear. As in Friedreich ataxia, selectively disrupted Fe-S cluster and mitochondrial iron homeostasis in neural cells may be involved. (See  <a class="medical medical_review" href="/z/d/html/6224.html" rel="external">"Friedreich ataxia", section on 'Pathogenesis'</a>.)</p><p></p><p class="headingAnchor" id="H3414339971"><span class="h3">Mitochondrial protein synthesis</span><span class="headingEndMark"> — </span>Sideroblastic anemias with multisystem manifestations are associated with diverse genetic defects involving mitochondrial proteins that are unrelated to heme synthesis and Fe-S protein production per se. While most proteins (&gt;1000) necessary for mitochondrial function are encoded by the nuclear genome and imported into the mitochondrion, there are 13 proteins encoded by the mitochondrial genome, which is maternally transmitted; these proteins represent components of respiratory chain complexes. For their translation, the mitochondrial genome encodes 12 mitochondrial transfer RNAs (tRNAs) and 2 mitochondrial ribosomal RNAs [<a href="#rid97">97</a>]. This dual genetic control of the mitochondrial proteins and their function adds to the difficulty in the interpretation of pathological findings and phenotypic features of these syndromes.</p><p>How these mitochondrial protein synthesis defects are linked to mitochondrial iron pathways or homeostasis leading to erythroblast mitochondrial iron overload and anemia remains elusive. Cellular hemoglobin production does not appear to be directly affected, as the erythrocytes are normal or macrocytic in most cases. The recurrent involvement of components of the respiratory chain in these syndromes may in part affect iron utilization in the erythroid cell, but the mechanism(s) is not understood [<a href="#rid98">98</a>]. The understanding of the genetic mitochondrial cytopathies is further obscured by the lack of an explanation as to why defects affect some tissues but not others.</p><p>The pathogenesis of seven syndromes involves components of the mitochondrial protein translation apparatus that often impacts complexes of the respiratory chain. (See <a class="local">'Syndromic forms'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heteroplasmy of large deletions, rearrangements, or duplications of mitochondrial DNA</strong> – These usually sporadic aberrations lead to the loss of multiple proteins encoded by the mitochondrial genome in Pearson syndrome (see <a class="local">'Pearson syndrome (large deletion of mitochondrial DNA)'</a> above). Approximately one-half of cases have a 4977 base pair deletion that involves mitochondrially encoded subunits of respiratory complexes I, IV, and V, as well as several mitochondrial tRNA genes. The heteroplasmic nature of mitochondrial DNA at the cellular and organ levels is thought to account for the high variability of tissues affected over time in this condition.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mitochondrial tyrosyl-tRNA synthetase (YARS2)</strong> – The synthetase YARS2 attaches tyrosine to its cognate tRNA. Mutations in <em>YARS2 </em>reduce levels of the enzyme and affect production of respiratory complex proteins encoded by the mitochondrial genome [<a href="#rid42">42</a>]. The high degree of variability in phenotype seen among siblings as well as in the same patient over time remains unexplained. (See <a class="local">'Myopathy, lactic acidosis, and sideroblastic anemia (pathogenic variants in IARS2, LARS2, MT-ATP6, NDUFB11, PUS1, SARS2, or YARS2)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mitochondrial leucyl-tRNA synthetase (LARS2)</strong> – The synthetase LARS2 attaches leucine to its cognate tRNA. Mutations in <em>LARS2</em> reduced enzyme activity and complex I protein levels, resulting in multisystem failure in one reported patient [<a href="#rid39">39</a>]. (See <a class="local">'Myopathy, lactic acidosis, and sideroblastic anemia (pathogenic variants in IARS2, LARS2, MT-ATP6, NDUFB11, PUS1, SARS2, or YARS2)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mitochondrial isoleucyl-tRNA synthetase (IARS2)</strong> – The synthetase IARS2 attaches isoleucine to its cognate tRNA. In addition to previously described pathogenic variants in the <em>IARS2</em> gene causing a range of overlapping clinical phenotypes in 18 patients, new variants have been added that were associated with neonatal sideroblastic anemia mimicking Pearson syndrome in three unrelated siblings [<a href="#rid46">46</a>]. Respiratory chain deficiency affecting erythropoiesis is implicated. (See <a class="local">'Myopathy, lactic acidosis, and sideroblastic anemia (pathogenic variants in IARS2, LARS2, MT-ATP6, NDUFB11, PUS1, SARS2, or YARS2)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mitochondrial seryl-tRNA synthetase (SARS2) </strong>–<strong> </strong>The synthetase SARS2 attaches serine to its cognate tRNA. Pathogenic variants in the <em>SARS2</em> gene, previously found in hyperuricemia, pulmonary hypertension, renal failure in infancy and alkalosis (HUPRA) syndrome or spastic paresis, were associated with sideroblastic anemia in a child who also co-inherited a spectrin abnormality causing hereditary spherocytosis [<a href="#rid47">47</a>]. In vitro culture studies of his CD34-positive cells showed markedly decreased cell proliferation, delayed erythroid maturation, and increased apoptosis; respiratory chain abnormalities were not found. (See <a class="local">'Myopathy, lactic acidosis, and sideroblastic anemia (pathogenic variants in IARS2, LARS2, MT-ATP6, NDUFB11, PUS1, SARS2, or YARS2)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pseudouridine synthase (PUS1)</strong> – Mutated <em>PUS1</em> results in defective pseudo-uridylation of uridine, destabilizing tRNA structures and likely causing faulty translation of mitochondrial genes of respiratory complexes I and IV [<a href="#rid99">99</a>]. (See <a class="local">'Myopathy, lactic acidosis, and sideroblastic anemia (pathogenic variants in IARS2, LARS2, MT-ATP6, NDUFB11, PUS1, SARS2, or YARS2)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>tRNA nucleotidyl transferase (TRNT1)</strong> – The TRNT1 enzyme is essential for processing all cytosolic and mitochondrial precursor tRNAs by adding the trinucleotide CCA to their 3" end for protein synthesis globally. As noted above (see <a class="local">'Sideroblastic anemia, B cell immunodeficiency, periodic fevers, and developmental delay (TRNT1 mutation)'</a> above), pathogenic variants in <em>TRNT1</em> lead to metabolic dysfunctions in multiple body systems, but their pathogenesis is not defined. At the cellular level, formation of respiratory chain complexes was impaired in patient-derived fibroblasts [<a href="#rid100">100</a>]. Dysfunctional TRNT1 proteins may be unstable and/or their CCA-adding catalytic activity may be affected [<a href="#rid51">51</a>]. The wide clinical spectrum of the disorder is attributed to genetic heterogeneity, resulting in dysregulated tRNA maturation and abundance with effects on translation of distinct proteins [<a href="#rid51">51,101</a>].</p><p></p><p class="headingAnchor" id="H2036376884"><span class="h4">Reversible inhibition of mitochondrial protein synthesis</span><span class="headingEndMark"> — </span>Two antibiotics, <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">chloramphenicol</a> and <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a>, which cause the ring sideroblast anemia phenotype, interfere with mitochondrial protein synthesis at the level of mRNA translation [<a href="#rid102">102</a>]. Impaired heme synthesis, evident in reduced FECH activity, appears to be a secondary effect [<a href="#rid94">94</a>]. (See <a class="local">'Medications'</a> above.)</p><p class="headingAnchor" id="H2967306310"><span class="h4">Oxidative phosphorylation</span><span class="headingEndMark"> — </span>Exceptionally, pathogenic variants in the genes for two proteins of the respiratory chain themselves are associated with sideroblastic anemia:</p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>NDUFB11</em></strong> – A recurrent mutation affecting the respiratory complex I-associated protein NDUFB11, which is encoded on the X chromosome, results in respiratory complex insufficiency and complex I instability. Impaired erythroid proliferation appears to be involved in the mechanism of the anemia [<a href="#rid41">41,48</a>]. (See <a class="local">'Myopathy, lactic acidosis, and sideroblastic anemia (pathogenic variants in IARS2, LARS2, MT-ATP6, NDUFB11, PUS1, SARS2, or YARS2)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>ATPase 6</strong> – A recurrent heteroplasmic mutation affecting the mitochondrial DNA-encoded ATPase 6 subunit of complex V (ATP synthase) is associated with variable mitochondrial respiratory impairment, which has not been further characterized [<a href="#rid40">40,45</a>]. Varying degrees of heteroplasmy correlate with variable clinical manifestations.</p><p></p><p class="headingAnchor" id="H125287488"><span class="h2">Sideroblastic anemias with incompletely understood pathogenesis</span><span class="headingEndMark"> — </span>In three forms of sideroblastic anemia, the pathophysiology is only suggested.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MDS/MPN variants with ring sideroblasts</strong> – Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) arise from acquired mutations in a hematopoietic progenitor cell, leading to overgrowth of a mutant clone with variable disruption of the normal maturation of the cell lineages. (See  <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a> and  <a class="medical medical_review" href="/z/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms"</a>.)</p><p></p><p class="bulletIndent1">In the MDS/MPN variants with ring sideroblasts, impaired heme synthesis has long been indicated by two consistent features: a hypochromic population of RBCs and an increased erythrocyte protoporphyrin level [<a href="#rid1">1</a>]. However, disorders impacting heme synthesis such as FECH deficiency or mutated cytochrome c oxidase were only found in some cases.</p><p></p><p class="bulletIndent1">The focus of research into the pathogenesis of these sideroblastic anemias has shifted to understanding the functional consequences of the commonly mutated <em>SF3B1</em> mentioned above. (See <a class="local">'Clonal (MDS/MPN subtypes)'</a> above.)</p><p></p><p class="bulletIndent1">Deregulation of genes implicated in congenital sideroblastic anemias has been found in gene expression studies. In erythroid precursor cells from patients with MDS/MPN variants with ring sideroblasts and <em>SF3B1</em> mutations, <em>ALAS2</em>, <em>HSPA9, GLRX5,</em> and<em> SLC25A37</em> are variably upregulated<em> </em>[<a href="#rid103">103,104</a>]. However, <em>ABCB7</em> has a reduced transcript and emerged as a leading candidate gene involved in causing the ring sideroblast abnormality [<a href="#rid103">103,105,106</a>]. Further, the aberrant splicing caused by mutant <em>SF3B1</em> produces a premature termination codon in the <em>ABCB7</em> mRNA, resulting in nonsense-mediated mRNA decay [<a href="#rid107">107</a>]. </p><p></p><p class="bulletIndent1">Experimental proof of <em>SF3B1</em> pathogenic variants underlying ring sideroblast production has been obtained in two in vitro models of induced pluripotent stem cells (iPSC) and HUDEP (human umbilical cord blood-derived erythroid progenitor)-2 cells derived from individuals with <em>SF3B1</em>-mutant MDS, with efficient ring sideroblast formation during in vitro erythroid differentiation [<a href="#rid108">108,109</a>]. Reduced protein expression of mis-spliced <em>ABCB7</em> and <em>TMEM14C</em> (the importer of protoporphyrinogen IX) and reversal of the ring sideroblast formation by functional rescue demonstrated that mis-spliced <em>ABCB7</em> and <em>TMEM14C</em> cause <em>SF3B1</em> mutant MDS [<a href="#rid108">108</a>]. </p><p></p><p class="bulletIndent1">Downstream, ABCB7 deficiency would cause impaired production of Fe-S cluster-containing proteins in the cytoplasm and thus indirectly affect heme synthesis as in XLSA/A. (See <a class="local">'X-linked sideroblastic anemia with ataxia (ABCB7 mutation)'</a> above and <a class="local">'Autosomal recessive congenital sideroblastic anemia (pathogenic variant in SLC25A38, GLRX5, HSPA9, HSCB, or FECH)'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thiamine-responsive megaloblastic anemia (TRMA)</strong> – The syndrome of megaloblastic anemia, non-type I diabetes mellitus and sensorineural deafness arises from biallelic pathogenic variants in a high-affinity thiamine transporter, <em>SLC19A2</em>. (See <a class="local">'Thiamine-responsive megaloblastic anemia (SLC19A2 mutation)'</a> above.)</p><p></p><p class="bulletIndent1">The pathophysiology of this syndrome is unclear, and multiple pathways appear to be involved. The megaloblastic anemia in TRMA was thought to result from defective nucleic acid synthesis attributed to cellular thiamine deficiency [<a href="#rid110">110</a>]. The associated ring sideroblasts observed in TRMA was hypothesized to relate to the role of thiamine in the production of succinyl-coenzyme A, a substrate of ALAS [<a href="#rid111">111</a>]. In that several thiamine-dependent enzymes involved in carbohydrate metabolism require the cofactor lipoic acid, production of which is mediated by the iron-sulfur containing enzyme lipoic acid synthetase, it is suggested to provide a potential link between thiamine metabolism and iron-sulfur cluster generation [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sideroblastic anemia associated with copper deficiency</strong> – Deficiency of copper normally does not occur in humans because of its adequate content in food. However, as mentioned above, nutritional copper deficiency is encountered in certain clinical settings as well as after excess ingestion of zinc. In these settings, copper deficiency typically leads to sideroblastic anemia, neutropenia, and neurologic deficits. (See <a class="local">'Copper deficiency'</a> above.)</p><p></p><p class="bulletIndent1">The copper deficiency associated with excess zinc ingestion occurs because zinc induces an increase in the intestinal metal-binding protein metallothionein. Metallothionein preferentially binds copper in the gut and prevents its absorption, thereby enhancing its excretion in sloughed intestinal cells and leading to clinical copper deficiency [<a href="#rid112">112</a>]. The anemia is normocytic or slightly macrocytic, but its pathogenesis has not been elucidated in humans.</p><p></p><p class="bulletIndent1">In classic studies of copper deficiency in experimental animals, in which the anemia is microcytic and hypochromic, heme synthesis in reticulocytes was not impaired. However, heme synthesis from ferric iron and protoporphyrin was decreased, suggesting that defective reduction of ferric iron to ferrous iron is linked to the observed diminished levels of the copper-containing enzyme cytochrome oxidase [<a href="#rid113">113</a>]. Moreover, intestinal absorption and mobilization of iron from macrophages and hepatocytes to transferrin was impaired because of the associated lack of the ferroxidase ceruloplasmin, which would limit the supply of iron to the bone marrow and contribute to the RBC microcytosis.</p><p></p><p class="bulletIndent1">It remains unclear why the acquired copper deficiency targets the hematopoietic and nervous systems with clinical consequences. With copper depletion, the essential role of the metal for the integrity of mitochondrial metabolism may be compromised in a tissue-specific manner. In one study it was found that copper depletion impairs differentiation of cord blood-derived hematopoietic progenitor cells, which may relate to the normocytic anemia, neutropenia, and sometimes observed thrombocytopenia in patients with copper deficiency [<a href="#rid114">114</a>]. </p><p></p><p class="headingAnchor" id="H2231337155"><span class="h2">Ineffective erythropoiesis and iron overload</span><span class="headingEndMark"> — </span>Ineffective erythropoiesis is a major feature of three common forms of sideroblastic anemia: those caused by defects in <em>ALAS2</em> (XLSA), <em>SLC25A38</em>, and in acquired clonal MDS/MPN with ring sideroblasts. The ineffective erythropoiesis leads to increased intestinal iron absorption and consequent systemic iron overload.</p><p class="headingAnchor" id="H2708212777"><span class="h3">Ineffective erythropoiesis</span><span class="headingEndMark"> — </span>Certain anemias are associated with ineffective erythropoiesis, in which the underlying defect renders RBC precursors unable to complete maturation and causes them to die prematurely within the bone marrow. This process is also called intramedullary hemolysis (to distinguish it from hemolysis within the circulation). In sideroblastic anemias with defective heme synthesis, impaired hemoglobin production disrupts erythroblast maturation and the faulty erythroblasts are destroyed via mechanisms such as apoptosis, similar to thalassemias [<a href="#rid115">115-117</a>]. Ineffective erythropoiesis is recognized morphologically by the disparate combination of intense erythroid hyperplasia in the bone marrow (due to anemia-induced increases in erythropoietin) and the absence of a reticulocytosis response in the peripheral blood. Kinetically, an increased plasma iron turnover rate and a reduced incorporation of iron into circulating RBCs is demonstrated.</p><p class="headingAnchor" id="H2843961694"><span class="h3">Iron overload</span><span class="headingEndMark"> — </span>Ineffective erythropoiesis results in inappropriately increased intestinal iron absorption via suppression of the erythroid iron regulatory hormone hepcidin, which is mediated by erythroferrone (ERFE) through its secretion by the expanded but ineffective erythron in the bone marrow [<a href="#rid118">118</a>]. This mechanism is reflected in low hepcidin and high circulating ERFE levels. Moreover, a variant ERFE is present in MDS with ring sideroblasts and pathogenic variants in <em>SF3B1</em> [<a href="#rid119">119</a>]. Concentrations of circulating ERFE are higher in such patients, implicating that the variant ERFE in particular contributes to the iron overload in clonal acquired sideroblastic anemias [<a href="#rid119">119</a>].</p><p>The iron overload is indistinguishable from that of hereditary hemochromatosis, both clinically and on liver biopsy (<a class="graphic graphic_picture graphicRef60882" href="/z/d/graphic/60882.html" rel="external">picture 2</a>); it is also referred to as "erythropoietic hemochromatosis." Its magnitude is most closely related to the duration of the disease and the degree of erythroid hyperplasia in the bone marrow [<a href="#rid120">120-122</a>]. In XLSA the iron burden has not always correlated with the severity of anemia, and cirrhosis may be encountered in asymptomatic individuals with mild or previously unrecognized anemia, or anemia that has responded to <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a>, due to the increased deposition of iron within the liver (<a class="graphic graphic_picture graphicRef62989" href="/z/d/graphic/62989.html" rel="external">picture 3</a>) [<a href="#rid120">120,123-125</a>]. Hepatocellular carcinoma developed in two reported cases [<a href="#rid79">79</a>]. Cardiomyopathy (<a class="graphic graphic_picture graphicRef81850" href="/z/d/graphic/81850.html" rel="external">picture 4</a>) and endocrine deficits may be seen.</p><p>The body iron burden is further increased by transfusions given for severe anemia or by inappropriate administration of iron based on an incorrect diagnosis of iron deficiency. Co-inheritance of a common hemochromatosis gene (<em>HFE</em>) variant such as C282Y or H63D, which would increase intestinal iron absorption, has been rarely observed [<a href="#rid126">126-128</a>]. Concomitant <em>HFE</em> variants were excluded in several patient series with congenital or acquired clonal sideroblastic anemia [<a href="#rid122">122</a>].</p><p>The extent to which iron overload accentuates the anemia in patients with sideroblastic anemia is difficult to assess. Instances in which anemia was improved by iron depletion have been reported [<a href="#rid129">129,130</a>]. These observations suggest that reducing iron overload may improve erythroblast mitochondrial function, erythropoiesis, and hypersplenism [<a href="#rid1">1</a>]. <a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">Pyridoxine</a> responsiveness may also be enhanced upon iron depletion in some cases of XLSA [<a href="#rid127">127</a>].</p><p class="headingAnchor" id="H2857067437"><span class="h1">DISORDERS OF HEME SYNTHESIS WITHOUT RING SIDEROBLASTS</span><span class="headingEndMark"> — </span>Many disorders of heme synthesis are not associated with sideroblastic anemia, as discussed in the following.</p><p class="headingAnchor" id="H3633182352"><span class="h2">Porphyrias</span><span class="headingEndMark"> — </span>Porphyrias are inherited disorders of heme biosynthesis, each caused by genetic defects in one of the eight enzymes of the heme biosynthesis pathway. Most porphyrias are not associated with compromised erythropoiesis, anemia, or the ring sideroblast abnormality, because the affected enzymes have tissue-specific expression and/or regulation predominantly in nonerythroid cells.</p><p>Exceptions include the following two porphyrias:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>EPP</strong> – As noted above, erythropoietic protoporphyria (EPP), which is caused by mutations affecting the enzyme ferrochelatase (FECH), can be associated with ring sideroblasts. (See <a class="local">'Autosomal recessive congenital sideroblastic anemia (pathogenic variant in SLC25A38, GLRX5, HSPA9, HSCB, or FECH)'</a> above and  <a class="medical medical_review" href="/z/d/html/7125.html" rel="external">"Erythropoietic protoporphyria and X-linked protoporphyria", section on 'EPP due to FECH variant'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CEP</strong> – Congenital erythropoietic porphyria (CEP) has a hemolytic anemia that is caused by marked accumulation of the heme synthesis intermediate isomer uroporphyrinogen I, but CEP is not associated with ring sideroblasts. (See  <a class="medical medical_review" href="/z/d/html/7101.html" rel="external">"Porphyrias: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/7102.html" rel="external">"Congenital erythropoietic porphyria"</a>.)</p><p></p><p class="headingAnchor" id="H287714792"><span class="h2">Lead poisoning</span><span class="headingEndMark"> — </span>Lead poisoning is frequently listed as a cause of sideroblastic anemia, and the anemia of lead poisoning results in part from inhibition of heme synthesis. However, authentic ring sideroblasts have not been convincingly documented in lead poisoning. On our review of the iron-stained bone marrow aspirate smears from 12 patients with established lead toxicity and anemia of varying severity, we were unable to detect ring sideroblasts in any of their bone marrow smears [<a href="#rid131">131</a>].</p><p>Lead inhibits most of the enzymes in the heme biosynthetic pathway to varying degrees, ALA dehydratase (ALAD) being the most sensitive [<a href="#rid69">69</a>]. Lead also limits iron delivery to ferrochelatase (FECH) in erythroid cells. As a result, zinc is inserted into protoporphyrin as a surrogate metal, producing zinc protoporphyrin, similar to the process that occurs in iron deficiency. The reduced availability of iron is likely responsible for the absence of ring sideroblasts in individuals with lead poisoning.</p><p>Lead poisoning can cause hemolysis as well as other manifestations in multiple organ systems. (See  <a class="medical medical_review" href="/z/d/html/6491.html" rel="external">"Childhood lead poisoning: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2773.html" rel="external">"Lead exposure, toxicity, and poisoning in adults"</a>.)</p><p class="headingAnchor" id="H3276816673"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Sideroblastic anemias are anemias in which ring sideroblasts are seen on a Prussian blue-stained bone marrow aspirate smear. Ring sideroblasts represent red blood cell (RBC) precursors in which pathologic iron deposits have accumulated in mitochondria in a perinuclear ring distribution (<a class="graphic graphic_picture graphicRef62536" href="/z/d/graphic/62536.html" rel="external">picture 1</a>). (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital causes</strong> – Congenital sideroblastic anemias are caused by a germline pathogenic variant in a nuclear or mitochondrial gene(s). They can be further classified into syndromic and nonsyndromic forms (<a class="graphic graphic_table graphicRef79712" href="/z/d/graphic/79712.html" rel="external">table 1</a>). Inheritance can be X-linked, autosomal recessive, or mitochondrial. The RBCs can be microcytic or normal-to-macrocytic (<a class="graphic graphic_table graphicRef108664" href="/z/d/graphic/108664.html" rel="external">table 2</a>). Specific genetic defects and their associated features are described above. (See <a class="local">'Congenital sideroblastic anemias'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MDS and MPNs</strong> – Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) are clonal hematopoietic disorders typically acquired in adulthood. Some MDS/MPN variants are characterized by ring sideroblasts, usually in the setting of an acquired mutation in <em>SF3B1</em>. (See <a class="local">'Clonal (MDS/MPN subtypes)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alcohol, medications, copper</strong> <strong>deficiency</strong> – Reversible acquired sideroblastic anemia can be caused by exposure to alcohol, certain medications (eg, <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> [INH], <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">chloramphenicol</a>, <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a>, and cytotoxic chemotherapy), and hypothermia; and by copper deficiency. (See <a class="local">'Reversible'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effects on heme</strong> <strong>synthesis </strong>– The pathophysiologic mechanisms of ring sideroblast formation are centered in erythroblast mitochondria and involve defective heme synthesis, deficient formation of iron-sulfur clusters for proteins regulating heme synthesis, or abnormalities in production of mitochondrial proteins in RBC precursors (<a class="graphic graphic_figure graphicRef86551" href="/z/d/graphic/86551.html" rel="external">figure 1</a>); these block the intracellular utilization of iron, resulting in its trapping and accumulation in mitochondria. Vitamin B6 (<a class="drug drug_general" data-topicid="9839" href="/z/d/drug information/9839.html" rel="external">pyridoxine</a>) is a cofactor for the initial heme synthetic enzyme 5-aminolevulinic acid synthase (ALAS2). Copper plays a role in mitochondrial redox reactions via cytochrome c oxidase. (See <a class="local">'Disrupted mitochondrial pathways in erythroid precursors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effects on RBC production</strong> – Several common sideroblastic anemias are associated with ineffective erythropoiesis, a process of disrupted erythroblast maturation with destruction in the bone marrow. Ineffective erythropoiesis in turn leads to suppressed hepcidin production, increased intestinal iron absorption, and systemic iron overload, which is further exacerbated by transfusions. (See <a class="local">'Ineffective erythropoiesis and iron overload'</a> above and  <a class="medical medical_review" href="/z/d/html/7105.html" rel="external">"Regulation of iron balance"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heme synthesis abnormalities that do not cause sideroblastic anemia</strong> – Pathogenic variants in all of the genes encoding heme synthetic enzymes cause porphyria without sideroblastic anemia with the exception of erythropoietic protoporphyria (EPP; associated with pathogenic variants in ferrochelatase [<em>FECH</em>]). In our experience, lead poisoning is not a cause of sideroblastic anemia. (See <a class="local">'Disorders of heme synthesis without ring sideroblasts'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and treatment</strong> – An approach to the evaluation, diagnosis, and treatment of sideroblastic anemias is presented separately. (See  <a class="medical medical_review" href="/z/d/html/7123.html" rel="external">"Sideroblastic anemias: Diagnosis and management"</a>.)</p><p></p><p class="headingAnchor" id="H38945510"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Hematology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Bottomley SS, Fleming MD. Sideroblastic anemias. In: Wintrobe's Clinical Hematology, 14th ed, Greer JP, Arber DA, Glader B, et al (Eds), Wolters Kluwer, Philadelphia 2019. p.644.</li><li><a class="nounderline abstract_t">Ducamp S, Fleming MD. The molecular genetics of sideroblastic anemia. Blood 2019; 133:59.</a></li><li><a class="nounderline abstract_t">Bergmann AK, Campagna DR, McLoughlin EM, et al. Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer 2010; 54:273.</a></li><li><a class="nounderline abstract_t">Liu G, Guo S, Kang H, et al. Mutation spectrum in Chinese patients affected by congenital sideroblastic anemia and a search for a genotype-phenotype relationship. Haematologica 2013; 98:e158.</a></li><li><a class="nounderline abstract_t">Ducamp S, Kannengiesser C, Touati M, et al. Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations. Hum Mutat 2011; 32:590.</a></li><li><a class="nounderline abstract_t">Nakajima O, Takahashi S, Harigae H, et al. Heme deficiency in erythroid lineage causes differentiation arrest and cytoplasmic iron overload. EMBO J 1999; 18:6282.</a></li><li><a class="nounderline abstract_t">Nakajima O, Okano S, Harada H, et al. Transgenic rescue of erythroid 5-aminolevulinate synthase-deficient mice results in the formation of ring sideroblasts and siderocytes. Genes Cells 2006; 11:685.</a></li><li><a class="nounderline abstract_t">Taylor JL, Brown BL. Structural basis for dysregulation of aminolevulinic acid synthase in human disease. J Biol Chem 2022; 298:101643.</a></li><li><a class="nounderline abstract_t">Kaneko K, Furuyama K, Fujiwara T, et al. Identification of a novel erythroid-specific enhancer for the ALAS2 gene and its loss-of-function mutation which is associated with congenital sideroblastic anemia. Haematologica 2014; 99:252.</a></li><li><a class="nounderline abstract_t">Campagna DR, de Bie CI, Schmitz-Abe K, et al. X-linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATA-binding site mutations. Am J Hematol 2014; 89:315.</a></li><li><a class="nounderline abstract_t">Bekri S, May A, Cotter PD, et al. A promoter mutation in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causes X-linked sideroblastic anemia. Blood 2003; 102:698.</a></li><li><a class="nounderline abstract_t">Cox TC, Bawden MJ, Abraham NG, et al. Erythroid 5-aminolevulinate synthase is located on the X chromosome. Am J Hum Genet 1990; 46:107.</a></li><li><a class="nounderline abstract_t">Bishop DF, Henderson AS, Astrin KH. Human delta-aminolevulinate synthase: assignment of the housekeeping gene to 3p21 and the erythroid-specific gene to the X chromosome. Genomics 1990; 7:207.</a></li><li><a class="nounderline abstract_t">Aivado M, Gattermann N, Rong A, et al. X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns. Blood Cells Mol Dis 2006; 37:40.</a></li><li><a class="nounderline abstract_t">Rose C, Callebaut I, Pascal L, et al. Lethal ALAS2 mutation in males X-linked sideroblastic anaemia. Br J Haematol 2016; 178:648.</a></li><li><a class="nounderline abstract_t">Bottomley SS, Wise PD, Wasson EG, et al. X-linked sideroblastic anemia in ten female probands due to ALAS2 mutations and skewed X chromosome inactivation. Am J Hum Genet 1998; 63(Suppl):A352.</a></li><li><a class="nounderline abstract_t">Cazzola M, May A, Bergamaschi G, et al. Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. Blood 2000; 96:4363.</a></li><li><a class="nounderline abstract_t">Heeney MM, Berhe S, Campagna DR, et al. SLC25A38 congenital sideroblastic anemia: Phenotypes and genotypes of 31 individuals from 24 families, including 11 novel mutations, and a review of the literature. Hum Mutat 2021; 42:1367.</a></li><li><a class="nounderline abstract_t">Guernsey DL, Jiang H, Campagna DR, et al. Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat Genet 2009; 41:651.</a></li><li><a class="nounderline abstract_t">Schmitz-Abe K, Ciesielski SJ, Schmidt PJ, et al. Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9. Blood 2015; 126:2734.</a></li><li><a class="nounderline abstract_t">Watanabe A, Fujiwara T, Ohta A, et al. HSPA9 frameshift and loss-of-function mutations in a patient manifesting syndromic sideroblastic anemia and congenital anomalies. Pediatr Blood Cancer 2023; 70:e29971.</a></li><li><a class="nounderline abstract_t">Crispin A, Guo C, Chen C, et al. Mutations in the iron-sulfur cluster biogenesis protein HSCB cause congenital sideroblastic anemia. J Clin Invest 2020; 130:5245.</a></li><li><a class="nounderline abstract_t">Ye H, Jeong SY, Ghosh MC, et al. Glutaredoxin 5 deficiency causes sideroblastic anemia by specifically impairing heme biosynthesis and depleting cytosolic iron in human erythroblasts. J Clin Invest 2010; 120:1749.</a></li><li><a class="nounderline abstract_t">Wingert RA, Galloway JL, Barut B, et al. Deficiency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesis. Nature 2005; 436:1035.</a></li><li><a class="nounderline abstract_t">Camaschella C, Campanella A, De Falco L, et al. The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood 2007; 110:1353.</a></li><li><a class="nounderline abstract_t">Liu G, Guo S, Anderson GJ, et al. Heterozygous missense mutations in the GLRX5 gene cause sideroblastic anemia in a Chinese patient. Blood 2014; 124:2750.</a></li><li><a class="nounderline abstract_t">Daher R, Mansouri A, Martelli A, et al. GLRX5 mutations impair heme biosynthetic enzymes ALA synthase 2 and ferrochelatase in Human congenital sideroblastic anemia. Mol Genet Metab 2019; 128:342.</a></li><li><a class="nounderline abstract_t">Scott AJ, Ansford AJ, Webster BH, Stringer HC. Erythropoietic protoporphyria with features of a sideroblastic anaemia terminating in liver failure. Am J Med 1973; 54:251.</a></li><li><a class="nounderline abstract_t">Rademakers LH, Koningsberger JC, Sorber CW, et al. Accumulation of iron in erythroblasts of patients with erythropoietic protoporphyria. Eur J Clin Invest 1993; 23:130.</a></li><li><a class="nounderline abstract_t">Bottomley SS, Tanaka M, Everett MA. Diminished erythroid ferrochelatase activity in protoporphyria. J Lab Clin Med 1975; 86:126.</a></li><li><a class="nounderline abstract_t">Pagon RA, Bird TD, Detter JC, Pierce I. Hereditary sideroblastic anaemia and ataxia: an X linked recessive disorder. J Med Genet 1985; 22:267.</a></li><li><a class="nounderline abstract_t">Pondarre C, Campagna DR, Antiochos B, et al. Abcb7, the gene responsible for X-linked sideroblastic anemia with ataxia, is essential for hematopoiesis. Blood 2007; 109:3567.</a></li><li><a class="nounderline abstract_t">Bekri S, Kispal G, Lange H, et al. Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation. Blood 2000; 96:3256.</a></li><li><a class="nounderline abstract_t">Allikmets R, Raskind WH, Hutchinson A, et al. Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum Mol Genet 1999; 8:743.</a></li><li><a class="nounderline abstract_t">Maguire A, Hellier K, Hammans S, May A. X-linked cerebellar ataxia and sideroblastic anaemia associated with a missense mutation in the ABC7 gene predicting V411L. Br J Haematol 2001; 115:910.</a></li><li><a class="nounderline abstract_t">D'Hooghe M, Selleslag D, Mortier G, et al. X-linked sideroblastic anemia and ataxia: a new family with identification of a fourth ABCB7 gene mutation. Eur J Paediatr Neurol 2012; 16:730.</a></li><li><a class="nounderline abstract_t">Casas KA, Fischel-Ghodsian N. Mitochondrial myopathy and sideroblastic anemia. Am J Med Genet A 2004; 125A:201.</a></li><li><a class="nounderline abstract_t">Bykhovskaya Y, Casas K, Mengesha E, et al. Missense mutation in pseudouridine synthase 1 (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA). Am J Hum Genet 2004; 74:1303.</a></li><li><a class="nounderline abstract_t">Riley LG, Rudinger-Thirion J, Schmitz-Abe K, et al. LARS2 Variants Associated with Hydrops, Lactic Acidosis, Sideroblastic Anemia, and Multisystem Failure. JIMD Rep 2016; 28:49.</a></li><li><a class="nounderline abstract_t">Burrage LC, Tang S, Wang J, et al. Mitochondrial myopathy, lactic acidosis, and sideroblastic anemia (MLASA) plus associated with a novel de novo mutation (m.8969G&gt;A) in the mitochondrial encoded ATP6 gene. Mol Genet Metab 2014; 113:207.</a></li><li><a class="nounderline abstract_t">Lichtenstein DA, Crispin AW, Sendamarai AK, et al. A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia. Blood 2016; 128:1913.</a></li><li><a class="nounderline abstract_t">Riley LG, Menezes MJ, Rudinger-Thirion J, et al. Phenotypic variability and identification of novel YARS2 mutations in YARS2 mitochondrial myopathy, lactic acidosis and sideroblastic anaemia. Orphanet J Rare Dis 2013; 8:193.</a></li><li><a class="nounderline abstract_t">Sommerville EW, Ng YS, Alston CL, et al. Clinical Features, Molecular Heterogeneity, and Prognostic Implications in YARS2-Related Mitochondrial Myopathy. JAMA Neurol 2017; 74:686.</a></li><li><a class="nounderline abstract_t">Riley LG, Heeney MM, Rudinger-Thirion J, et al. The phenotypic spectrum of germline YARS2 variants: from isolated sideroblastic anemia to mitochondrial myopathy, lactic acidosis and sideroblastic anemia 2. Haematologica 2018; 103:2008.</a></li><li><a class="nounderline abstract_t">Berhe S, Heeney MM, Campagna DR, et al. Recurrent heteroplasmy for the MT-ATP6 p.Ser148Asn (m.8969G&gt;A) mutation in patients with syndromic congenital sideroblastic anemia of variable clinical severity. Haematologica 2018; 103:e561.</a></li><li><a class="nounderline abstract_t">Barcia G, Pandithan D, Ruzzenente B, et al. Biallelic IARS2 mutations presenting as sideroblastic anemia. Haematologica 2021; 106:1220.</a></li><li><a class="nounderline abstract_t">Colin E, Courtois G, Brouzes C, et al. Biallelic mutations in the SARS2 gene presenting as congenital sideroblastic anemia. Haematologica 2021; 106:3202.</a></li><li><a class="nounderline abstract_t">Torraco A, Bianchi M, Verrigni D, et al. A novel mutation in NDUFB11 unveils a new clinical phenotype associated with lactic acidosis and sideroblastic anemia. Clin Genet 2017; 91:441.</a></li><li><a class="nounderline abstract_t">Wiseman DH, May A, Jolles S, et al. A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). Blood 2013; 122:112.</a></li><li><a class="nounderline abstract_t">Chakraborty PK, Schmitz-Abe K, Kennedy EK, et al. Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood 2014; 124:2867.</a></li><li><a class="nounderline abstract_t">Slade A, Kattini R, Campbell C, Holcik M. Diseases Associated with Defects in tRNA CCA Addition. Int J Mol Sci 2020; 21.</a></li><li><a class="nounderline abstract_t">Li Y, Deng M, Han T, et al. Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD). J Clin Immunol 2023; 43:780.</a></li><li><a class="nounderline abstract_t">Wild KT, Goldstein AC, Muraresku C, Ganetzky RD. Broadening the phenotypic spectrum of Pearson syndrome: Five new cases and a review of the literature. Am J Med Genet A 2020; 182:365.</a></li><li><a class="nounderline abstract_t">Rötig A, Bourgeron T, Chretien D, et al. Spectrum of mitochondrial DNA rearrangements in the Pearson marrow-pancreas syndrome. Hum Mol Genet 1995; 4:1327.</a></li><li><a class="nounderline abstract_t">Bader-Meunier B, Miélot F, Breton-Gorius J, et al. Hematologic involvement in mitochondrial cytopathies in childhood: a retrospective study of bone marrow smears. Pediatr Res 1999; 46:158.</a></li><li><a class="nounderline abstract_t">Bergmann AK, Sahai I, Falcone JF, et al. Thiamine-responsive megaloblastic anemia: identification of novel compound heterozygotes and mutation update. J Pediatr 2009; 155:888.</a></li><li><a class="nounderline abstract_t">Labay V, Raz T, Baron D, et al. Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness. Nat Genet 1999; 22:300.</a></li><li><a class="nounderline abstract_t">Fleming JC, Tartaglini E, Steinkamp MP, et al. The gene mutated in thiamine-responsive anaemia with diabetes and deafness (TRMA) encodes a functional thiamine transporter. Nat Genet 1999; 22:305.</a></li><li><a class="nounderline abstract_t">Diaz GA, Banikazemi M, Oishi K, et al. Mutations in a new gene encoding a thiamine transporter cause thiamine-responsive megaloblastic anaemia syndrome. Nat Genet 1999; 22:309.</a></li><li><a class="nounderline abstract_t">Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391.</a></li><li><a class="nounderline abstract_t">Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365:1384.</a></li><li><a class="nounderline abstract_t">Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts and RARS with thrombocytosis. Am J Hematol 2015; 90:549.</a></li><li><a class="nounderline abstract_t">Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478:64.</a></li><li><a class="nounderline abstract_t">Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood 2020; 136:157.</a></li><li><a class="nounderline abstract_t">Visconte V, Rogers HJ, Singh J, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood 2012; 120:3173.</a></li><li><a class="nounderline abstract_t">Sarkany RP, Ross G, Willis F. Acquired erythropoietic protoporphyria as a result of myelodysplasia causing loss of chromosome 18. Br J Dermatol 2006; 155:464.</a></li><li><a class="nounderline abstract_t">Gattermann N, Retzlaff S, Wang YL, et al. Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia. Blood 1997; 90:4961.</a></li><li><a class="nounderline abstract_t">Savage D, Lindenbaum J. Anemia in alcoholics. Medicine (Baltimore) 1986; 65:322.</a></li><li class="breakAll">Bottomley SS. Sideroblastic anaemia. In: Iron in Biochemistry and Medicine II, Jacobs A, Worwood M (Eds), Academic Press, London 1980. p.363.</li><li><a class="nounderline abstract_t">Saini N, Jacobson JO, Jha S, et al. The perils of not digging deep enough--uncovering a rare cause of acquired anemia. Am J Hematol 2012; 87:413.</a></li><li><a class="nounderline abstract_t">Willekens C, Dumezy F, Boyer T, et al. Linezolid induces ring sideroblasts. Haematologica 2013; 98:e138.</a></li><li><a class="nounderline abstract_t">Liapis K, Vrachiolias G, Spanoudakis E, Kotsianidis I. Vacuolation of early erythroblasts with ring sideroblasts: a clue to the diagnosis of linezolid toxicity. Br J Haematol 2020; 190:809.</a></li><li><a class="nounderline abstract_t">Ok CY, Medeiros LJ, Hu Y, et al. Transient/reversible ring sideroblasts in bone marrow of patients post cytotoxic therapies for primary malignancies. Leuk Res 2011; 35:1605.</a></li><li><a class="nounderline abstract_t">Chen Z, Wang SA, Goswami M, et al. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts. Leuk Res 2019; 86:106227.</a></li><li><a class="nounderline abstract_t">Bolton KL, Ptashkin RN, Gao T, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet 2020; 52:1219.</a></li><li><a class="nounderline abstract_t">O'Brien H, Amess JA, Mollin DL. Recurrent thrombocytopenia, erythroid hypoplasia and sideroblastic anaemia associated with hypothermia. Br J Haematol 1982; 51:451.</a></li><li><a class="nounderline abstract_t">Mohamed S, Ibrahim F, Alasafar MN, et al. Recurrent sideroblastic anemia during pregnancy. Clin Case Rep 2023; 11:e6814.</a></li><li><a class="nounderline abstract_t">Natelson EA. Pregnancy-induced pancytopenia with cellular bone marrow: distinctive hematologic features. Am J Med Sci 2006; 332:205.</a></li><li><a class="nounderline abstract_t">Bottomley SS, Fleming MD. Sideroblastic anemia: diagnosis and management. Hematol Oncol Clin North Am 2014; 28:653.</a></li><li><a class="nounderline abstract_t">Bottomley SS. The spectrum and role of iron overload in sideroblastic anemia. Ann N Y Acad Sci 1988; 526:331.</a></li><li><a class="nounderline abstract_t">May A, de Souza P, Barnes K, et al. Erythroblast iron metabolism in sideroblastic marrows. Br J Haematol 1982; 52:611.</a></li><li><a class="nounderline abstract_t">Levi S, Corsi B, Bosisio M, et al. A human mitochondrial ferritin encoded by an intronless gene. J Biol Chem 2001; 276:24437.</a></li><li><a class="nounderline abstract_t">Cazzola M, Invernizzi R, Bergamaschi G, et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 2003; 101:1996.</a></li><li><a class="nounderline abstract_t">Maio N, Zhang DL, Ghosh MC, et al. Mechanisms of cellular iron sensing, regulation of erythropoiesis and mitochondrial iron utilization. Semin Hematol 2021; 58:161.</a></li><li><a class="nounderline abstract_t">Astner I, Schulze JO, van den Heuvel J, et al. Crystal structure of 5-aminolevulinate synthase, the first enzyme of heme biosynthesis, and its link to XLSA in humans. EMBO J 2005; 24:3166.</a></li><li><a class="nounderline abstract_t">Shoolingin-Jordan PM, Al-Daihan S, Alexeev D, et al. 5-Aminolevulinic acid synthase: mechanism, mutations and medicine. Biochim Biophys Acta 2003; 1647:361.</a></li><li><a class="nounderline abstract_t">Nzelu D, Shangaris P, Story L, et al. X-linked sideroblastic anaemia in a female fetus: a case report and a literature review. BMC Med Genomics 2021; 14:296.</a></li><li><a class="nounderline abstract_t">Harigae H, Furuyama K, Kudo K, et al. A novel mutation of the erythroid-specific gamma-Aminolevulinate synthase gene in a patient with non-inherited pyridoxine-responsive sideroblastic anemia. Am J Hematol 1999; 62:112.</a></li><li><a class="nounderline abstract_t">Cox TC, Bottomley SS, Wiley JS, et al. X-linked pyridoxine-responsive sideroblastic anemia due to a Thr388-to-Ser substitution in erythroid 5-aminolevulinate synthase. N Engl J Med 1994; 330:675.</a></li><li><a class="nounderline abstract_t">Lunetti P, Damiano F, De Benedetto G, et al. Characterization of Human and Yeast Mitochondrial Glycine Carriers with Implications for Heme Biosynthesis and Anemia. J Biol Chem 2016; 291:19746.</a></li><li><a class="nounderline abstract_t">Andolfo I, Martone S, Ribersani M, et al. Apparent recessive inheritance of sideroblastic anemia type 2 due to uniparental isodisomy at the SLC25A38 locus. Haematologica 2020; 105:2883.</a></li><li><a class="nounderline abstract_t">Holme SA, Worwood M, Anstey AV, et al. Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. Blood 2007; 110:4108.</a></li><li><a class="nounderline abstract_t">Fratz-Berilla EJ, Breydo L, Gouya L, et al. Isoniazid inhibits human erythroid 5-aminolevulinate synthase: Molecular mechanism and tolerance study with four X-linked protoporphyria patients. Biochim Biophys Acta 2017; 1863:428.</a></li><li><a class="nounderline abstract_t">Yunis AA, Salem Z. Drug-induced mitochondrial damage and sideroblastic change. Clin Haematol 1980; 9:607.</a></li><li><a class="nounderline abstract_t">Maio N, Rouault TA. Mammalian iron sulfur cluster biogenesis: From assembly to delivery to recipient proteins with a focus on novel targets of the chaperone and co-chaperone proteins. IUBMB Life 2022; 74:684.</a></li><li><a class="nounderline abstract_t">Maio N, Kim KS, Holmes-Hampton G, et al. Dimeric ferrochelatase bridges ABCB7 and ABCB10 homodimers in an architecturally defined molecular complex required for heme biosynthesis. Haematologica 2019; 104:1756.</a></li><li><a class="nounderline abstract_t">Suzuki T, Nagao A, Suzuki T. Human mitochondrial tRNAs: biogenesis, function, structural aspects, and diseases. Annu Rev Genet 2011; 45:299.</a></li><li><a class="nounderline abstract_t">Gattermann N. Iron rusting in the mitochondria? Blood 2016; 128:1907.</a></li><li><a class="nounderline abstract_t">Patton JR, Bykhovskaya Y, Mengesha E, et al. Mitochondrial myopathy and sideroblastic anemia (MLASA): missense mutation in the pseudouridine synthase 1 (PUS1) gene is associated with the loss of tRNA pseudouridylation. J Biol Chem 2005; 280:19823.</a></li><li><a class="nounderline abstract_t">Liwak-Muir U, Mamady H, Naas T, et al. Impaired activity of CCA-adding enzyme TRNT1 impacts OXPHOS complexes and cellular respiration in SIFD patient-derived fibroblasts. Orphanet J Rare Dis 2016; 11:79.</a></li><li><a class="nounderline abstract_t">Fatica T, Naas T, Liwak U, et al. TRNT-1 Deficiency Is Associated with Loss of tRNA Integrity and Imbalance of Distinct Proteins. Genes (Basel) 2023; 14.</a></li><li><a class="nounderline abstract_t">Kloss P, Xiong L, Shinabarger DL, Mankin AS. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol 1999; 294:93.</a></li><li><a class="nounderline abstract_t">Dolatshad H, Pellagatti A, Liberante FG, et al. Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes. Leukemia 2016; 30:2322.</a></li><li><a class="nounderline abstract_t">del Rey M, Benito R, Fontanillo C, et al. Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblasts. PLoS One 2015; 10:e0126555.</a></li><li><a class="nounderline abstract_t">Nikpour M, Scharenberg C, Liu A, et al. The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. Leukemia 2013; 27:889.</a></li><li><a class="nounderline abstract_t">Boultwood J, Pellagatti A, Nikpour M, et al. The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One 2008; 3:e1970.</a></li><li><a class="nounderline abstract_t">Dolatshad H, Pellagatti A, Fernandez-Mercado M, et al. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. Leukemia 2015; 29:1092.</a></li><li><a class="nounderline abstract_t">Clough CA, Pangallo J, Sarchi M, et al. Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome. Blood 2022; 139:2038.</a></li><li><a class="nounderline abstract_t">Ochi T, Fujiwara T, Ono K, et al. Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome. Sci Rep 2022; 12:14562.</a></li><li><a class="nounderline abstract_t">Boros LG, Steinkamp MP, Fleming JC, et al. Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA). Blood 2003; 102:3556.</a></li><li><a class="nounderline abstract_t">Abboud MR, Alexander D, Najjar SS. Diabetes mellitus, thiamine-dependent megaloblastic anemia, and sensorineural deafness associated with deficient alpha-ketoglutarate dehydrogenase activity. J Pediatr 1985; 107:537.</a></li><li><a class="nounderline abstract_t">Cousins RJ. Absorption, transport, and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin. Physiol Rev 1985; 65:238.</a></li><li><a class="nounderline abstract_t">Williams DM, Loukopoulos D, Lee GR, Cartwright GE. Role of copper in mitochondrial iron metabolism. Blood 1976; 48:77.</a></li><li><a class="nounderline abstract_t">Peled T, Glukhman E, Hasson N, et al. Chelatable cellular copper modulates differentiation and self-renewal of cord blood-derived hematopoietic progenitor cells. Exp Hematol 2005; 33:1092.</a></li><li><a class="nounderline abstract_t">Matthes TW, Meyer G, Samii K, Beris P. Increased apoptosis in acquired sideroblastic anaemia. Br J Haematol 2000; 111:843.</a></li><li><a class="nounderline abstract_t">Hellström-Lindberg E, Schmidt-Mende J, Forsblom AM, et al. Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Haematol 2001; 112:714.</a></li><li><a class="nounderline abstract_t">Tehranchi R, Invernizzi R, Grandien A, et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood 2005; 106:247.</a></li><li><a class="nounderline abstract_t">Srole DN, Ganz T. Erythroferrone structure, function, and physiology: Iron homeostasis and beyond. J Cell Physiol 2021; 236:4888.</a></li><li><a class="nounderline abstract_t">Bondu S, Alary AS, Lefèvre C, et al. A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome. Sci Transl Med 2019; 11.</a></li><li><a class="nounderline abstract_t">Peto TE, Pippard MJ, Weatherall DJ. Iron overload in mild sideroblastic anaemias. Lancet 1983; 1:375.</a></li><li><a class="nounderline abstract_t">Cazzola M, Barosi G, Bergamaschi G, et al. Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemias. Br J Haematol 1983; 54:649.</a></li><li class="breakAll">Bottomley SS. Iron overload in sideroblastic and other non-thalassemic anemias. In: Hemochromatosis. Genetics, Pathophysiology, Diagnosis and Treatment, Barton JC, Edwards CQ (Eds), Cambridge University Press, Cambridge 2000. p.442.</li><li><a class="nounderline abstract_t">Marcus RE. Iron overload in mild sideroblastic anaemia. Lancet 1983; 1:1276.</a></li><li><a class="nounderline abstract_t">Bottomley SS. Sideroblastic anemia: Death from iron overload. Hosp Pract 1991; 26(suppl 3):55.</a></li><li><a class="nounderline abstract_t">Heller T, Höchstetter V, Basler M, Borck V. [Vitamin B6-sensitive hereditary sideroblastic anemia]. Dtsch Med Wochenschr 2004; 129:141.</a></li><li><a class="nounderline abstract_t">Yaouanq J, Grosbois B, Jouanolle AM, et al. Haemochromatosis Cys282Tyr mutation in pyridoxine-responsive sideroblastic anaemia. Lancet 1997; 349:1475.</a></li><li><a class="nounderline abstract_t">Cotter PD, May A, Li L, et al. Four new mutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia: increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis. Blood 1999; 93:1757.</a></li><li><a class="nounderline abstract_t">Nearman ZP, Szpurka H, Serio B, et al. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol 2007; 82:1076.</a></li><li><a class="nounderline abstract_t">French TJ, Jacobs P. Sideroblastic anaemia associated with iron overload treated by repeated phlebotomy. S Afr Med J 1976; 50:594.</a></li><li><a class="nounderline abstract_t">Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94:288.</a></li><li><a class="nounderline abstract_t">Bottomley SS, Muller-Eberhard U. Pathophysiology of heme synthesis. Semin Hematol 1988; 25:282.</a></li></ol></div><div id="topicVersionRevision">Topic 7122 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Bottomley SS, Fleming MD. Sideroblastic anemias. In: Wintrobe's Clinical Hematology, 14th ed, Greer JP, Arber DA, Glader B, et al (Eds), Wolters Kluwer, Philadelphia 2019. p.644.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30401706" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The molecular genetics of sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19731322" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24323989" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mutation spectrum in Chinese patients affected by congenital sideroblastic anemia and a search for a genotype-phenotype relationship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21309041" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10562540" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Heme deficiency in erythroid lineage causes differentiation arrest and cytoplasmic iron overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16716198" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Transgenic rescue of erythroid 5-aminolevulinate synthase-deficient mice results in the formation of ring sideroblasts and siderocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35093382" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Structural basis for dysregulation of aminolevulinic acid synthase in human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23935018" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Identification of a novel erythroid-specific enhancer for the ALAS2 gene and its loss-of-function mutation which is associated with congenital sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24166784" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : X-linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATA-binding site mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12663458" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A promoter mutation in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causes X-linked sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2294742" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Erythroid 5-aminolevulinate synthase is located on the X chromosome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2347585" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Human delta-aminolevulinate synthase: assignment of the housekeeping gene to 3p21 and the erythroid-specific gene to the X chromosome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16735131" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27292130" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Lethal ALAS2 mutation in males X-linked sideroblastic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : X-linked sideroblastic anemia in ten female probands due to ALAS2 mutations and skewed X chromosome inactivation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11110715" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34298585" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : SLC25A38 congenital sideroblastic anemia: Phenotypes and genotypes of 31 individuals from 24 families, including 11 novel mutations, and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19412178" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26491070" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36094340" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : HSPA9 frameshift and loss-of-function mutations in a patient manifesting syndromic sideroblastic anemia and congenital anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32634119" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mutations in the iron-sulfur cluster biogenesis protein HSCB cause congenital sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20364084" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Glutaredoxin 5 deficiency causes sideroblastic anemia by specifically impairing heme biosynthesis and depleting cytosolic iron in human erythroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16110529" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Deficiency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17485548" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25342667" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Heterozygous missense mutations in the GLRX5 gene cause sideroblastic anemia in a Chinese patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30660387" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : GLRX5 mutations impair heme biosynthetic enzymes ALA synthase 2 and ferrochelatase in Human congenital sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4685849" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Erythropoietic protoporphyria with features of a sideroblastic anaemia terminating in liver failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8462622" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Accumulation of iron in erythroblasts of patients with erythropoietic protoporphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1151134" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Diminished erythroid ferrochelatase activity in protoporphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4045952" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hereditary sideroblastic anaemia and ataxia: an X linked recessive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17192398" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Abcb7, the gene responsible for X-linked sideroblastic anemia with ataxia, is essential for hematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11050011" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10196363" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11843825" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : X-linked cerebellar ataxia and sideroblastic anaemia associated with a missense mutation in the ABC7 gene predicting V411L.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22398176" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : X-linked sideroblastic anemia and ataxia: a new family with identification of a fourth ABCB7 gene mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981724" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Mitochondrial myopathy and sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15108122" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Missense mutation in pseudouridine synthase 1 (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26537577" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : LARS2 Variants Associated with Hydrops, Lactic Acidosis, Sideroblastic Anemia, and Multisystem Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25037980" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mitochondrial myopathy, lactic acidosis, and sideroblastic anemia (MLASA) plus associated with a novel de novo mutation (m.8969G&gt;A) in the mitochondrial encoded ATP6 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27488349" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24344687" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Phenotypic variability and identification of novel YARS2 mutations in YARS2 mitochondrial myopathy, lactic acidosis and sideroblastic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28395030" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical Features, Molecular Heterogeneity, and Prognostic Implications in YARS2-Related Mitochondrial Myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30026338" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The phenotypic spectrum of germline YARS2 variants: from isolated sideroblastic anemia to mitochondrial myopathy, lactic acidosis and sideroblastic anemia 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30006447" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Recurrent heteroplasmy for the MT-ATP6 p.Ser148Asn (m.8969G&gt;A) mutation in patients with syndromic congenital sideroblastic anemia of variable clinical severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33327715" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Biallelic IARS2 mutations presenting as sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34407605" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Biallelic mutations in the SARS2 gene presenting as congenital sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27102574" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A novel mutation in NDUFB11 unveils a new clinical phenotype associated with lactic acidosis and sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23553769" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25193871" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32471101" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Diseases Associated with Defects in tRNA CCA Addition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36729249" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31825167" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Broadening the phenotypic spectrum of Pearson syndrome: Five new cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7581370" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Spectrum of mitochondrial DNA rearrangements in the Pearson marrow-pancreas syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10447108" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hematologic involvement in mitochondrial cytopathies in childhood: a retrospective study of bone marrow smears.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19643445" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Thiamine-responsive megaloblastic anemia: identification of novel compound heterozygotes and mutation update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10391221" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10391222" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The gene mutated in thiamine-responsive anaemia with diabetes and deafness (TRMA) encodes a functional thiamine transporter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10391223" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Mutations in a new gene encoding a thiamine transporter cause thiamine-responsive megaloblastic anaemia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27069254" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21995386" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25899435" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Refractory anemia with ring sideroblasts and RARS with thrombocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21909114" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Frequent pathway mutations of splicing machinery in myelodysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32347921" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22826563" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16882191" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Acquired erythropoietic protoporphyria as a result of myelodysplasia causing loss of chromosome 18.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9389715" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3747828" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Anemia in alcoholics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3747828" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Anemia in alcoholics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22120958" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The perils of not digging deep enough--uncovering a rare cause of acquired anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24186315" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Linezolid induces ring sideroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32510577" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Vacuolation of early erythroblasts with ring sideroblasts: a clue to the diagnosis of linezolid toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21596435" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Transient/reversible ring sideroblasts in bone marrow of patients post cytotoxic therapies for primary malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31557598" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33106634" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Cancer therapy shapes the fitness landscape of clonal hematopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7104229" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Recurrent thrombocytopenia, erythroid hypoplasia and sideroblastic anaemia associated with hypothermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36644616" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Recurrent sideroblastic anemia during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17031246" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Pregnancy-induced pancytopenia with cellular bone marrow: distinctive hematologic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25064706" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Sideroblastic anemia: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The spectrum and role of iron overload in sideroblastic anemia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7138790" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Erythroblast iron metabolism in sideroblastic marrows.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11323407" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A human mitochondrial ferritin encoded by an intronless gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12406866" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34389108" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Mechanisms of cellular iron sensing, regulation of erythropoiesis and mitochondrial iron utilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16121195" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Crystal structure of 5-aminolevulinate synthase, the first enzyme of heme biosynthesis, and its link to XLSA in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12686158" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : 5-Aminolevulinic acid synthase: mechanism, mutations and medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34930268" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : X-linked sideroblastic anaemia in a female fetus: a case report and a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10577279" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A novel mutation of the erythroid-specific gamma-Aminolevulinate synthase gene in a patient with non-inherited pyridoxine-responsive sideroblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8107717" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : X-linked pyridoxine-responsive sideroblastic anemia due to a Thr388-to-Ser substitution in erythroid 5-aminolevulinate synthase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27476175" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Characterization of Human and Yeast Mitochondrial Glycine Carriers with Implications for Heme Biosynthesis and Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33256393" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Apparent recessive inheritance of sideroblastic anemia type 2 due to uniparental isodisomy at the SLC25A38 locus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17804693" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27838491" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Isoniazid inhibits human erythroid 5-aminolevulinate synthase: Molecular mechanism and tolerance study with four X-linked protoporphyria patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7004688" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Drug-induced mitochondrial damage and sideroblastic change.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35080107" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Mammalian iron sulfur cluster biogenesis: From assembly to delivery to recipient proteins with a focus on novel targets of the chaperone and co-chaperone proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30765471" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Dimeric ferrochelatase bridges ABCB7 and ABCB10 homodimers in an architecturally defined molecular complex required for heme biosynthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21910628" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Human mitochondrial tRNAs: biogenesis, function, structural aspects, and diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27737844" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Iron rusting in the mitochondria?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15772074" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Mitochondrial myopathy and sideroblastic anemia (MLASA): missense mutation in the pseudouridine synthase 1 (PUS1) gene is associated with the loss of tRNA pseudouridylation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27317422" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Impaired activity of CCA-adding enzyme TRNT1 impacts OXPHOS complexes and cellular respiration in SIFD patient-derived fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37239403" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : TRNT-1 Deficiency Is Associated with Loss of tRNA Integrity and Imbalance of Distinct Proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10556031" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27211273" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25955609" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23070040" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18398482" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25428262" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34861039" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36028755" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12893755" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4045602" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Diabetes mellitus, thiamine-dependent megaloblastic anemia, and sensorineural deafness associated with deficient alpha-ketoglutarate dehydrogenase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3885271" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Absorption, transport, and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/947406" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Role of copper in mitochondrial iron metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16219531" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Chelatable cellular copper modulates differentiation and self-renewal of cord blood-derived hematopoietic progenitor cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11122146" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Increased apoptosis in acquired sideroblastic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11260077" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15755901" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33372284" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Erythroferrone structure, function, and physiology: Iron homeostasis and beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31292266" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6130377" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Iron overload in mild sideroblastic anaemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6871111" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6871111" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6134064" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Iron overload in mild sideroblastic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Sideroblastic anemia: Death from iron overload</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14724775" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : [Vitamin B6-sensitive hereditary sideroblastic anemia].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9164339" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Haemochromatosis Cys282Tyr mutation in pyridoxine-responsive sideroblastic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10029606" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Four new mutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia: increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17654685" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1265557" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Sideroblastic anaemia associated with iron overload treated by repeated phlebotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8759889" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3064310" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Pathophysiology of heme synthesis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
